Engineered toxins: new therapeutics.
Clostridial neurotoxins possess discrete structural domains with distinct pharmacological properties. Aspects of neurotoxin function with therapeutic potential include specific neuronal binding, intracellular (cytosolic) delivery of biologically active protein and inhibition of SNARE-mediated secretion. Understanding the structure function relationship of the neurotoxin protein enables the creation of recombinant proteins incorporating select domains of the neurotoxins to produce novel proteins with therapeutic potential in a range of clinical applications.
Foster
Keith A
KA
Syntaxin Ltd., Units 4-10, The Quadrant Barton Lane, Abingdon, Oxon, OX14 3YS, UK. keith.foster@syntaxin.com
D000818:Animals; D001905:Botulinum Toxins / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D015195:Drug Design; D006801:Humans; D009498:Neurotoxins / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D011487:Protein Conformation; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013744:Tetanus Toxin / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology
D009498:Neurotoxins; D011994:Recombinant Proteins; D013744:Tetanus Toxin; D001905:Botulinum Toxins